MedTrace Logo

Effects of Lansoprazole on Bone Turnover Markers

NCT04814316 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-01-25

No results posted yet for this study

Summary

Use of proton pump inhibitors (PPI) has increased in recent years. There are concerns that PPIs have possible negative effects on bone metabolism. It has been suggested that PPIs may reduce the absorption of calcium from the small intestine and lead to bone resorption by affecting osteoclastic activity. In this study, it is planned to investigate the effects of lansoprazole, a proton pump inhibitor, on bone turnover markers in pediatric patients with gastroesophageal reflux or gastroesophageal reflux disease.

Conditions

  • Bone Turnover Rate Disorder
  • Calcium Metabolism Disorders

Interventions

DIAGNOSTIC_TEST

Blood and urine specimens

Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Principal Investigators

  • Ali Islek, MD · Ataturk University School of Medicine

Eligibility

Min Age
16 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2021-06-30
Completion
2021-07-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814316 on ClinicalTrials.gov